Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3862MR)

This product GTTS-WQ3862MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3862MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8093MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ14670MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ14156MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ9597MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ6481MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ2542MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ10948MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ14246MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW